Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 13;13(2):304.
doi: 10.3390/diagnostics13020304.

Role of Iron Deficiency in Heart Failure-Clinical and Treatment Approach: An Overview

Affiliations
Review

Role of Iron Deficiency in Heart Failure-Clinical and Treatment Approach: An Overview

Cristina Elena Singer et al. Diagnostics (Basel). .

Abstract

Background: The association of chronic heart failure (CHF) and iron deficiency (ID) with or without anemia is frequently encountered in current medical practice and has a negative prognostic impact, worsening patients' exercise capacity and increasing hospitalization costs. Moreover, anemia is common in patients with chronic kidney disease (CKD) and CHF, an association known as cardio-renal anemia syndrome (CRAS) possessing a significantly increased risk of death.

Aim: This review aims to provide an illustrative survey on the impact of ID in CHF patients-based on physiopathological traits, clinical features, and the correlation between functional and absolute ID with CHF-and the benefit of iron supplementation in CHF.

Method: We selected the most recent publications with important scientific content covering the association of CHF and ID with or without anemia.

Discussions: An intricate physiopathological interplay is described in these patients-decrease in erythropoietin levels, activation of the renin-angiotensin-aldosterone system, systemic inflammation, and increases in hepcidin levels. These mechanisms amplify anemia, CHF, and CKD severity and worsen patients' outcomes.

Conclusions: Anemia is frequently encountered in CHF and represents a negative prognostic factor. Data from randomized controlled trials have underlined the administration of intravenous iron therapy (ferric carboxymaltose) as the only viable treatment option, with beneficial effects on quality of life and exercise capacity in patients with ID and systolic heart failure.

Keywords: chronic heart failure; hemoglobin; iron deficiency anemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Therapeutical agents used in CHF management and their pathogenic mechanisms. ARB, angiotensin receptor blockers. ACE, angiotensin-converting enzyme. AcSDKP, N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. ↑ = elevated value.
Figure 2
Figure 2
Physiopathology of cardio-renal anemia syndrome. EPO, erythropoietin. RAAS, renin-angiotensin-aldosterone system. ↑ = elevated value, ↓ = decreased value.
Figure 3
Figure 3
Therapeutical management of iron deficiency.

Similar articles

Cited by

References

    1. Dunn L.L., Rahmanto Y.S., Richardson D.R. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007;17:93–100. doi: 10.1016/j.tcb.2006.12.003. - DOI - PubMed
    1. Cairo G., Bernuzzi F., Recalcati S. A precious metal: Iron, an essential nutrient for all cells. Genes Nutr. 2006;1:25–39. doi: 10.1007/BF02829934. - DOI - PMC - PubMed
    1. Lippi G., Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med. J. 2020;5:15. doi: 10.21037/amj.2020.03.03. - DOI
    1. Anand I.S., Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018;138:80–98. doi: 10.1161/CIRCULATIONAHA.118.030099. - DOI - PubMed
    1. Camaschella C. New insights into iron deficiency and iron deficiency anemia. Blood Rev. 2017;31:225–233. doi: 10.1016/j.blre.2017.02.004. - DOI - PubMed

LinkOut - more resources